Paricalcitol (** Zemplar (brand name), also available as generic paricalcitol **)

Other Medications

EU EMA Approved ES Funded by SNS other indication 1 Clinical Trials

Description

Paricalcitol is primarily used for the treatment of secondary hyperparathyroidism and renal osteodystrophy associated with chronic kidney disease, not as a direct therapy for colorectal cancer. Its role in oncology is related to its potential anti-inflammatory effects that may indirectly benefit patients undergoing chemotherapy.

Mechanism of Action

Paricalcitol is a synthetic vitamin D analog that acts by binding to the vitamin D receptor (VDR), leading to increased calcium absorption and bone mineralization; it also has anti-inflammatory and immune-modulating effects.

Side Effects

Hypercalcemia; hyperparathyroidism suppression; renal impairment; bone pain

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT01197664 Phase 1
Archived
Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery
United States

Quick Info

Brand Name** Zemplar (brand name), also available as generic paricalcitol **
CategoryOther Medications
EU EMA StatusEMA Approved
ES Spain AccessFunded by SNS other indication
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.